Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.43 |
| ▸ | PNMT | P11086 | 3/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15724660 | 1.00 | PBRM1 (0.60) | PBRM1TDP1RAB9ANPC1ADRA2A | |
| SCHEMBL29891564 | 1.00 | PBRM1 (0.60) | PBRM1TDP1RAB9ANPC1ADRA2A | |
| SCHEMBL18114486 | 0.85 | PBRM1 (0.56) | PBRM1TDP1RAB9ANPC1ADRA2A | |
| SCHEMBL17233208 | 0.81 | PBRM1 (0.49) | PBRM1TDP1ADRA2APNMTADRA2B | |
| SCHEMBL17321070 | 0.81 | PBRM1 (0.49) | PBRM1TDP1ADRA2APNMTADRA2B | |
| SCHEMBL15667383 | 0.78 | TDP1 (0.57) | PBRM1TDP1RAB9ANPC1CASP3 | |
| SCHEMBL15667344 | 0.78 | TDP1 (0.57) | PBRM1TDP1RAB9ANPC1CASP3 | |
| SCHEMBL318360 | 0.78 | TDP1 (0.57) | PBRM1TDP1RAB9ANPC1CASP3 | |
| SCHEMBL15724650 | 0.77 | TDP1 (0.56) | PBRM1TDP1RAB9ANPC1CASP3 | |
| SCHEMBL5541364 | 0.77 | TDP1 (0.60) | PBRM1TDP1RAB9ANPC1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3640241-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-09-28 | — | — | EP | disclosed |
| US-6849649-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| US-6660756-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-12-09 | — | — | US | disclosed |
| EP-0177448-B1 | PROCESS FOR THE PREPARATION OF 1,2-BENZOXATHIIN DERIVATIVES | CIBA-GEIGY AG (CH) | 1989-05-03 | — | — | EP | disclosed |
| EP-0099339-B1 | CONDENSED N-PHENYLSULFONYL-N'-PYRIMIDINYL AND TRIAZINYL UREA | CIBA-GEIGY AG (CH) | 1987-01-07 | — | — | EP | disclosed |
| US-4634465-A | PRE- AND POSTEMERGENCE HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1987-01-06 | — | — | US | disclosed |
| US-4603211-A | Process for the preparation of 1,2-benzoxathiine derivatives | CIBA-GEIGY CORPORATION (US) | 1986-07-29 | — | — | US | disclosed |
| EP-0177448-A2 | Process for the preparation of 1,2-benzoxathiin derivatives | CIBA-GEIGY AG (CH) | 1986-04-09 | — | — | EP | disclosed |
| US-4560771-A | REACTING A DIHYDROBENZOFURAN DERIVATIVE WITH CHLOROSULFONIC ACID | CIBA GEIGY CORPORATION (US) | 1985-12-24 | — | — | US | disclosed |
| EP-0099339-A2 | Condensed N-phenylsulfonyl-N'-pyrimidinyl and triazinyl urea | CIBA-GEIGY AG (CH) | 1984-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | PBRM1 3409/4885TDP1 1336/4885RAB9A 599/4885 |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | PBRM1 144/4885TDP1 1684/4885RAB9A 3279/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | PBRM1 3409/4885TDP1 1336/4885RAB9A 599/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | PBRM1 144/4885TDP1 1684/4885RAB9A 3279/4885 |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | PBRM1 3409/4885TDP1 1336/4885RAB9A 599/4885 |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | PBRM1 4454/4885TDP1 1854/4885RAB9A 3818/4885 |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | PBRM1 3409/4885TDP1 1336/4885RAB9A 599/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | PBRM1 144/4885TDP1 1684/4885RAB9A 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.